Global CAR-T Therapy For B-Cell Malignancies Market Growth (Status and Outlook) 2025-2031

The global CAR-T Therapy For B-Cell Malignancies market size is predicted to grow from US$ 3503 million in 2025 to US$ 8245 million in 2031; it is expected to grow at a CAGR of 15.3% from 2025 to 2031.

Chimeric antigen receptor T (CAR-T) cell therapy is an individualized immunotherapy method that uses genetic engineering technology to modify the patient's own T cells to express chimeric antigen receptors (CAR) that can recognize specific antigens on the surface of cancer cells, thereby accurately killing tumor cells. In B-cell malignancies such as B-cell lymphoma, acute lymphoblastic leukemia, multiple myeloma, etc., CAR-T therapy mainly targets B-cell surface antigens (such as CD19, CD20, BCMA) and has become an important treatment option for recurrent or refractory patients.

In recent years, the market size of CAR-T therapy for B-cell malignancies has been continuously expanding. The main driving factors of the market include the increase of the incidence rate of B cell malignant tumors, the progress of related technologies (such as genetic engineering technology, cell production technology, drug delivery system), and the policy support of governments of various countries. The main participants in the market include internationally renowned companies such as Gilead, Roche, Novartis, as well as domestic companies such as Fosun Kite Bio, JW Therapeutics, and CARsgen Therapeutics. These companies are continuously increasing their R&D investment and developing innovative CAR-T therapies to meet clinical needs. The research on CAR-T therapy in B-cell malignancies mainly focuses on improving efficacy and prolonging patient survival. The main bottlenecks in the market are high treatment costs, complex preparation processes, potential side effects, indications limitations, and supply chain issues. The future trend of the industry is the research and development of universal CAR-T, the expansion of application areas (especially in the field of solid tumors), and more policy support. Enterprises will focus on improving the accessibility and safety of CAR-T therapy, developing new target antigens, and promoting the development of combination therapies. In addition, advances in gene editing technology may also bring new opportunities for CAR-T therapy. With the approval of more CAR-T products and the accumulation of clinical data, the CAR-T therapy market for B-cell malignancies is expected to continue to grow in the coming years.

LPI (LP Information)' newest research report, the “CAR-T Therapy For B-Cell Malignancies Industry Forecast” looks at past sales and reviews total world CAR-T Therapy For B-Cell Malignancies sales in 2024, providing a comprehensive analysis by region and market sector of projected CAR-T Therapy For B-Cell Malignancies sales for 2025 through 2031. With CAR-T Therapy For B-Cell Malignancies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CAR-T Therapy For B-Cell Malignancies industry.

This Insight Report provides a comprehensive analysis of the global CAR-T Therapy For B-Cell Malignancies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on CAR-T Therapy For B-Cell Malignancies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CAR-T Therapy For B-Cell Malignancies market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CAR-T Therapy For B-Cell Malignancies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CAR-T Therapy For B-Cell Malignancies.

This report presents a comprehensive overview, market shares, and growth opportunities of CAR-T Therapy For B-Cell Malignancies market by product type, application, key players and key regions and countries.

Segmentation by Type:
Single Target CAR-T
Dual Targets CAR-T
Multi Targets CAR-T
Universal CAR-T
Gene Modified Enhanced CAR-T

Segmentation by Application:
B-Cell Acute Lymphoblastic Leukemia
B-Cell Non-Hodgkin's Lymphoma
Multiple Myeloma
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Gilead Sciences
Roche
Novartis
Regeneron Pharmaceuticals
Bristol Myers Squibb
Celgene
Johnson And Johnson
Bluebird Bio
Kite Pharma
AstraZeneca
Fosun Kite Bio
JW Therapeutics
CARsgen Therapeutics
IMCURE
HEBECELL
Legend Biotech
Beihai Biotechnology
Chongqing Precision Biotech

Please note: The report will take approximately 2 business days to prepare and deliver.